This is intending to advance the development of personalised medicines, improve drug efficacy and outcomes in patients with specific chronic disorders by combining dose-optimised drug therapy with digital care.
Dr Paul Goldsmith is chief medical officer and innovation officer, co-founder and president of Closed Loop Medicine.
He said: “As clinicians, we know that dosing of drugs is a huge problem. In the most extreme cases, we are seeing patients having severe adverse events, for example when required to change dose levels to undergo surgery. Being able to predict personalised dose levels could be transformational.”
This strategic partnership harnesses Closed Loop Medicine’s SaMD and combines it with Teva’s pharmaceutical products creating the opportunity for digital companions to be prescribed alongside traditional therapeutics, enabling real-world data integration and improved effectiveness of innovative and known medicines.
Recent clinical trial results for a hypertension product, CLM-HT01, have demonstrated the technology’s ability to dose optimise drug therapy and minimise side effects whilst achieving blood pressure control, with exceptionally high medication adherence.
Dr Hakim Yadi OBE, CEO & Co-Founder of Closed Loop Medicine, commented: “It is a fantastic opportunity to be working with the Teva team to explore ways in which our combined expertise can advance the delivery of personalised medicine solutions, globally.
“The integration of real-world data enables personalisation of dosing that has historically not been readily available to clinicians before. This commercial partnership is an example of the potential and scalability of our SaMD technology platform, demonstrating the value that can be added by integrating software to well-known and trusted brands to improve disease management and patient outcomes at an individual level.”
The companies know the modern healthcare system aspires to personalized medicine, aiming to tailor treatments to individual patients. However, they say current medical practices often involve prescribing medications based on their average effects in a population, rather than optimizing dosages for each person.
The companies agree the one-size-fits-all approach can lead to increased side effects, adverse reactions, medication non-adherence, and ultimately, poorer patient outcomes. Additionally, they say, it can result in higher healthcare costs for payors. For instance, in a published article, in PubMed, researchers say they found that in 2016, drug-related morbidity and mortality costs were estimated at $528.4 billion in the US, and the projected annual cost of adverse drug reactions to the NHS alone was £2.21 billion.
Kim Innes, Teva’s general manager, UK & Ireland, said: “We are excited to be working with Closed Loop Medicine, who have demonstrated themselves to be compelling innovators in the area of personalised medicine. We know that the patient experience can sometimes be less than optimal and as the largest supplier of medicines to the NHS, the potential to combine ‘drug’ & ‘digital’ could create significant improvements to the lives of patients at great scale. We are very excited about the future of this partnership.”
